Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MI › Allen Park › NPI 1073587937
Lab

Joint Venture Hospital Laboratories

Joint Venture Hospital Laboratories was paid $56.38M by Medicaid between Jan 2018 and Nov 2024, across 566 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 6.5% of everything it billed.

33Billing provider infoJOINT VENTURE HOSPITAL LABORATORIES
ALLEN PARK, MI 48101
33aNPI1073587937assigned 02/15/2006
33bProvider typeClinical Medical Laboratory
28Total paid$56.38M
24GClaims4,794,967
24DCodes billed566
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#1 of 108
Median peer was paid$588K
This provider vs. median96×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M$6.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20184,768,394$56.35M
20197,865$11K
20203,984$6K
20211,705$376.74
20224,576$3K
20235,810$5K
2024incomplete2,633$2K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 6.5% 121,584 118,646 $3.65M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 6.3% 118,136 115,299 $3.55M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 6.0% 26,514 19,913 $3.36M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 5.4% 128,241 127,273 $3.02M
80053 Comprehensive metabolic panel 4.7% 302,126 287,298 $2.67M
80061 Lipid panel 4.1% 235,600 233,590 $2.34M
84443 Thyroid stimulating hormone (TSH) 4.1% 240,727 237,011 $2.33M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 3.4% 363,669 337,136 $1.89M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3.0% 42,871 40,159 $1.69M
83036 Hemoglobin; glycosylated (A1C) 1.9% 161,851 160,181 $1.08M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.9% 34,377 33,855 $1.05M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.6% 47,973 47,642 $914K
554 more codes
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.6% 18,686 $901K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.5% 27,555 $846K
82607 1.3% 70,422 $745K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.2% 29,429 $698K
86003 1.2% 8,327 $698K
84439 1.2% 100,398 $670K
88305 Level IV - Surgical pathology, gross and microscopic examination 1.1% 25,601 $604K
80074 <1% 15,262 $542K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 2,057 $482K
82728 <1% 43,850 $478K
87480 <1% 27,962 $471K
87510 <1% 27,936 $470K
87660 <1% 26,606 $442K
80048 Basic metabolic panel (calcium, ionized) <1% 61,221 $437K
87086 Culture, bacterial; quantitative colony count, urine <1% 85,639 $436K
87631 <1% 3,461 $368K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 3,931 $354K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 11,555 $334K
87902 <1% 1,570 $330K
88142 <1% 17,918 $323K
83013 <1% 5,606 $308K
85027 <1% 67,487 $300K
87536 <1% 4,810 $295K
82746 <1% 25,288 $267K
86780 <1% 21,332 $250K
87340 <1% 29,075 $250K
87070 <1% 34,772 $250K
84702 <1% 31,678 $248K
83655 <1% 25,554 $245K
87522 Neg quan hep c or qual rna <1% 6,546 $244K
84403 <1% 13,002 $243K
86803 <1% 24,244 $238K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 3,185 $236K
83970 <1% 6,752 $234K
84481 <1% 16,365 $226K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 14,455 $220K
87186 <1% 24,859 $214K
83516 <1% 7,989 $211K
86480 <1% 4,224 $211K
84153 <1% 14,034 $207K
86696 <1% 11,860 $196K
87653 <1% 5,968 $188K
83550 <1% 32,219 $187K
81001 <1% 80,297 $186K
83540 <1% 44,997 $185K
87077 <1% 23,857 $185K
87081 <1% 38,634 $182K
83735 <1% 40,655 $181K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 2,983 $166K
87529 <1% 3,208 $157K
83880 <1% 5,264 $154K
36415 Collection of venous blood by venipuncture <1% 257,398 $153K
83001 <1% 11,478 $147K
87390 <1% 11,911 $143K
84480 <1% 11,782 $142K
84146 <1% 9,657 $140K
86235 <1% 4,731 $139K
87088 <1% 21,554 $138K
85610 <1% 45,234 $137K
82105 <1% 9,943 $131K
86038 <1% 16,579 $129K
86360 <1% 3,892 $128K
82043 <1% 39,568 $127K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 998 $124K
83002 <1% 8,891 $124K
86850 <1% 22,640 $122K
80081 <1% 1,993 $122K
86702 <1% 11,937 $115K
82670 <1% 6,605 $110K
84460 <1% 32,333 $107K
82565 <1% 32,624 $107K
86706 <1% 12,843 $106K
86140 <1% 26,901 $105K
82784 <1% 8,520 $104K
88342 <1% 2,760 $104K
82570 <1% 30,786 $104K
84550 <1% 35,357 $103K
84450 <1% 31,480 $102K
80076 <1% 18,086 $100K
80055 <1% 2,979 $98K
88185 <1% 695 $97K
86592 <1% 33,984 $96K
86762 <1% 10,705 $93K
84466 <1% 8,689 $90K
82785 <1% 6,862 $90K
88341 <1% 1,187 $88K
86359 <1% 3,034 $88K
87632 <1% 513 $88K
86701 <1% 12,323 $88K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 5,502 $87K
88307 <1% 930 $85K
86695 <1% 10,069 $83K
82274 <1% 5,348 $79K
82652 <1% 2,511 $79K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 6,748 $74K
86376 <1% 5,925 $73K
81229 <1% 291 $70K
87901 <1% 357 $68K
82947 <1% 25,840 $68K
86901 <1% 22,964 $67K
82627 <1% 3,608 $67K
85652 <1% 29,168 $67K
80051 <1% 14,023 $66K
82550 <1% 15,105 $65K
83690 <1% 13,159 $64K
86200 <1% 5,544 $63K
84402 <1% 3,458 $63K
86147 <1% 1,885 $63K
84520 <1% 25,239 $62K
82248 <1% 14,855 $62K
88312 <1% 1,673 $58K
84144 <1% 3,936 $58K
83615 <1% 14,799 $58K
86832 <1% 380 $58K
86160 <1% 3,726 $57K
82731 <1% 1,021 $57K
86833 <1% 376 $55K
84100 <1% 18,586 $54K
80069 <1% 7,470 $54K
86800 <1% 4,077 $53K
82677 <1% 2,684 $53K
82247 <1% 12,987 $52K
86787 <1% 6,140 $51K
86225 <1% 4,939 $50K
86708 <1% 5,493 $50K
83021 <1% 3,995 $49K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 745 $49K
85730 <1% 12,649 $49K
86704 <1% 5,453 $48K
86039 <1% 4,997 $48K
86665 <1% 2,762 $47K
86900 <1% 22,845 $47K
82150 <1% 10,797 $47K
82951 <1% 4,580 $46K
87205 <1% 12,844 $46K
81003 <1% 33,708 $46K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 1,074 $45K
82533 <1% 3,327 $45K
84112 <1% 607 $45K
88304 <1% 3,181 $44K
87808 <1% 4,190 $44K
86255 <1% 3,416 $43K
81025 <1% 9,223 $43K
86141 <1% 3,790 $42K
86431 <1% 9,263 $42K
83020 <1% 4,404 $42K
83525 <1% 4,187 $41K
82378 <1% 3,038 $40K
88112 <1% 2,201 $40K
87517 <1% 1,057 $39K
82024 <1% 1,218 $39K
84165 <1% 4,859 $39K
82950 <1% 10,575 $39K
80164 <1% 3,808 $38K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 2,965 $38K
84436 <1% 7,071 $38K
86146 <1% 976 $37K
80305 <1% 5,036 $37K
86336 <1% 2,760 $37K
87493 <1% 1,181 $36K
87209 <1% 2,482 $35K
80197 <1% 3,642 $35K
84425 <1% 2,674 $35K
87147 <1% 7,110 $35K
84445 <1% 805 $34K
88173 <1% 794 $34K
82977 <1% 7,582 $33K
88321 <1% 665 $32K
86304 <1% 1,987 $32K
86317 <1% 701 $32K
87400 <1% 2,610 $30K
87799 <1% 915 $30K
86334 <1% 1,748 $30K
84703 <1% 6,107 $30K
83883 <1% 1,525 $30K
83090 <1% 2,076 $29K
84484 <1% 2,446 $28K
87625 <1% 811 $28K
87507 <1% 74 $27K
87045 <1% 3,389 $27K
87046 <1% 2,878 $27K
87210 <1% 8,893 $27K
88141 <1% 1,565 $27K
86352 <1% 315 $27K
81401 <1% 592 $26K
86694 <1% 2,926 $26K
87505 <1% 228 $25K
88313 <1% 696 $25K
81206 <1% 279 $25K
84156 <1% 9,943 $24K
84154 <1% 1,668 $24K
82088 <1% 822 $24K
82040 <1% 7,643 $23K
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 734 $23K
86300 <1% 1,208 $22K
84075 <1% 7,310 $22K
81270 <1% 299 $22K
84311 <1% 4,077 $22K
86922 <1% 964 $22K
85651 <1% 8,928 $22K
86812 <1% 996 $22K
81241 <1% 595 $22K
85046 <1% 5,722 $22K
84270 <1% 2,082 $22K
88262 <1% 277 $21K
87899 <1% 1,400 $21K
87427 <1% 1,471 $21K
84134 <1% 2,567 $20K
86008 <1% 242 $20K
82747 <1% 1,832 $20K
87906 <1% 178 $20K
87900 <1% 185 $20K
88184 <1% 663 $20K
84207 <1% 1,332 $20K
84681 <1% 1,296 $19K
82330 <1% 2,178 $19K
84305 <1% 1,276 $19K
85660 <1% 5,592 $19K
G0432 Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening <1% 1,612 $19K
87338 <1% 1,745 $19K
87177 <1% 2,610 $19K
83921 <1% 1,373 $19K
83498 <1% 1,086 $18K
81002 <1% 11,589 $18K
83721 <1% 3,583 $18K
80202 <1% 1,800 $18K
82310 <1% 5,721 $18K
85018 <1% 8,847 $18K
86664 <1% 2,060 $18K
86703 <1% 1,694 $17K
87641 <1% 561 $17K
86430 <1% 4,510 $17K
88230 <1% 247 $17K
83010 <1% 1,703 $17K
87497 <1% 451 $17K
82962 <1% 5,631 $17K
86301 <1% 1,026 $16K
86256 <1% 1,139 $16K
83993 <1% 1,234 $15K
86709 <1% 1,812 $15K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 1,351 $15K
83520 <1% 1,351 $15K
82465 <1% 5,370 $15K
87581 <1% 511 $15K
87486 <1% 487 $14K
86705 <1% 1,663 $14K
84630 <1% 1,711 $14K
80177 <1% 1,279 $14K
86870 <1% 964 $13K
86162 <1% 832 $13K
81240 <1% 434 $13K
85045 <1% 3,894 $13K
87075 <1% 1,711 $13K
85240 <1% 1,015 $13K
87329 <1% 1,241 $13K
84432 <1% 1,066 $12K
82140 <1% 1,297 $12K
86355 <1% 424 $12K
86618 <1% 1,176 $12K
87449 <1% 1,228 $12K
84244 <1% 741 $12K
86735 <1% 1,456 $12K
85379 <1% 1,586 $12K
86902 <1% 1,002 $12K
87324 <1% 1,165 $12K
84166 <1% 936 $12K
87797 <1% 629 $12K
87496 <1% 481 $12K
86357 <1% 391 $12K
86663 <1% 1,481 $12K
80178 <1% 2,044 $11K
84155 <1% 5,077 $11K
86765 <1% 1,433 $11K
85613 <1% 1,415 $11K
85014 <1% 5,549 $11K
87102 <1% 2,020 $11K
87040 <1% 1,219 $11K
82103 <1% 1,057 $11K
86335 <1% 469 $11K
83630 <1% 772 $10K
83519 <1% 502 $10K
86644 <1% 1,229 $10K
80159 <1% 656 $10K
G0475 Hiv antigen/antibody, combination assay, screening <1% 2,457 $10K
86923 <1% 1,245 $10K
82626 <1% 548 $10K
82525 <1% 1,101 $10K
86645 <1% 996 $10K
82787 <1% 476 $9K
84410 <1% 310 $9K
86777 <1% 1,086 $9K
83986 <1% 4,560 $9K
84132 <1% 3,065 $9K
80299 <1% 466 $9K
85245 <1% 663 $9K
82390 <1% 1,058 $9K
85007 <1% 3,484 $8K
87498 <1% 270 $8K
88143 <1% 439 $8K
80306 <1% 835 $8K
86308 <1% 2,134 $8K
82157 <1% 502 $8K
82164 <1% 837 $8K
83835 <1% 628 $8K
87184 <1% 1,288 $8K
85246 <1% 543 $8K
85306 <1% 641 $8K
80156 <1% 766 $8K
88360 <1% 132 $8K
87420 <1% 774 $8K
82672 <1% 486 $8K
82172 <1% 861 $8K
84590 <1% 898 $8K
82952 <1% 2,363 $7K
80185 <1% 804 $7K
86677 <1% 807 $7K
85303 <1% 645 $7K
88237 <1% 96 $7K
87252 <1% 445 $7K
82805 <1% 184 $7K
81207 <1% 79 $7K
87328 <1% 687 $7K
86356 <1% 347 $7K
83704 <1% 299 $7K
86481 <1% 119 $7K
82668 <1% 435 $7K
87640 <1% 249 $7K
85576 <1% 409 $7K
85300 <1% 619 $7K
87634 <1% 185 $7K
80175 <1% 578 $7K
86829 <1% 249 $6K
86361 <1% 333 $6K
83014 <1% 902 $6K
83605 <1% 848 $6K
88350 <1% 86 $6K
84163 <1% 717 $6K
80158 <1% 466 $6K
85244 <1% 362 $6K
88108 <1% 338 $6K
86880 <1% 1,466 $6K
84478 <1% 1,575 $5K
86341 <1% 402 $5K
83718 <1% 1,045 $5K
86778 <1% 643 $5K
87350 <1% 542 $5K
81511 <1% 502 $5K
87425 <1% 476 $5K
87150 <1% 147 $5K
81243 <1% 197 $5K
85384 <1% 742 $5K
87481 <1% 179 $5K
87807 <1% 476 $5K
88302 <1% 348 $5K
87511 <1% 179 $5K
82232 <1% 315 $4K
80183 <1% 417 $4K
82239 <1% 438 $4K
84080 <1% 529 $4K
82542 <1% 1,444 $4K
84446 <1% 399 $4K
87521 Neg quan hep c or qual rna <1% 156 $4K
82575 <1% 662 $4K
82175 <1% 285 $4K
86707 <1% 476 $4K
82530 <1% 303 $4K
86738 <1% 385 $4K
81374 <1% 81 $4K
87109 <1% 328 $4K
86580 <1% 985 $4K
86747 <1% 258 $4K
87430 <1% 373 $4K
82384 <1% 214 $4K
87106 <1% 415 $4K
82365 <1% 375 $4K
83003 <1% 221 $4K
82397 <1% 201 $4K
82340 <1% 916 $4K
88104 <1% 167 $4K
84255 <1% 251 $3K
80165 <1% 284 $3K
82671 <1% 141 $3K
82085 <1% 620 $3K
88271 <1% 71 $3K
86920 <1% 443 $3K
82553 <1% 430 $3K
36416 <1% 1,439 $3K
86593 <1% 832 $3K
83825 <1% 287 $3K
86060 <1% 589 $3K
87305 <1% 357 $3K
82803 <1% 234 $3K
84295 <1% 1,009 $3K
87015 <1% 716 $3K
86617 <1% 138 $3K
81256 <1% 93 $3K
85347 <1% 484 $3K
85060 <1% 408 $3K
80162 <1% 308 $3K
82180 <1% 415 $3K
86337 <1% 202 $3K
83037 <1% 545 $3K
86671 <1% 223 $3K
86316 <1% 162 $3K
86611 <1% 143 $2K
86001 <1% 133 $2K
87101 <1% 463 $2K
80186 <1% 245 $2K
81373 <1% 25 $2K
87181 <1% 451 $2K
88346 <1% 96 $2K
81015 <1% 1,168 $2K
82679 <1% 140 $2K
88311 <1% 403 $2K
85597 <1% 214 $2K
82955 <1% 298 $2K
85732 <1% 491 $2K
84300 <1% 709 $2K
85302 <1% 201 $2K
86215 <1% 221 $2K
81403 <1% 29 $2K
82379 <1% 157 $2K
88275 <1% 57 $2K
85305 <1% 192 $2K
88172 <1% 120 $2K
89060 <1% 413 $2K
83935 <1% 403 $2K
80184 <1% 216 $2K
83874 <1% 196 $2K
89051 <1% 479 $2K
84482 <1% 146 $2K
89055 <1% 495 $2K
86790 <1% 229 $2K
82272 <1% 728 $2K
86606 <1% 159 $2K
84442 <1% 135 $2K
83695 <1% 178 $2K
83930 <1% 342 $2K
85049 <1% 443 $2K
86340 <1% 134 $2K
88300 <1% 336 $2K
82656 <1% 149 $2K
86886 <1% 299 $2K
87535 <1% 54 $2K
85598 <1% 115 $2K
82270 <1% 648 $2K
87206 <1% 338 $1K
83789 <1% 137 $1K
87276 <1% 127 $1K
85250 <1% 104 $1K
87275 <1% 126 $1K
87116 <1% 232 $1K
84238 <1% 93 $1K
81000 <1% 618 $1K
88344 <1% 20 $1K
87255 <1% 44 $1K
89320 <1% 181 $1K
87385 <1% 116 $1K
87220 <1% 488 $1K
82507 <1% 89 $1K
82435 <1% 522 $1K
88235 <1% 13 $1K
82044 <1% 425 $1K
82139 <1% 94 $1K
81291 <1% 147 $1K
83497 <1% 111 $1K
82945 <1% 367 $1K
82552 <1% 101 $1K
87107 <1% 126 $1K
87254 <1% 224 $1K
84479 <1% 292 $1K
84133 <1% 321 $1K
82131 <1% 98 $1K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 153 $1K
82436 <1% 303 $1K
83916 <1% 54 $1K
85397 <1% 48 $1K
82104 <1% 197 $1K
85247 <1% 49 $1K
85390 <1% 109 $994.22
82017 <1% 98 $971.40
85048 <1% 450 $949.26
82948 <1% 349 $939.07
80201 <1% 108 $925.89
88280 <1% 48 $906.84
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 2,654 $887.62
87503 <1% 48 $876.20
87800 <1% 25 $871.98
82010 <1% 148 $863.03
87185 <1% 251 $853.37
83050 <1% 246 $845.68
84157 <1% 341 $835.81
85301 <1% 111 $832.32
81050 <1% 475 $820.88
82610 <1% 223 $807.70
89050 <1% 277 $781.15
82595 <1% 130 $748.03
84560 <1% 222 $740.50
85307 <1% 51 $733.18
84585 <1% 56 $713.32
85044 <1% 205 $703.50
86698 <1% 56 $701.19
82300 <1% 57 $686.77
87501 <1% 14 $658.05
86905 <1% 154 $651.21
85520 <1% 72 $629.76
88164 <1% 57 $625.00
82540 <1% 157 $574.27
85230 <1% 38 $543.47
84591 <1% 54 $533.55
82438 <1% 118 $527.09
80047 <1% 52 $488.32
80502 <1% 12 $457.60
82042 <1% 111 $430.80
85549 <1% 45 $425.91
88285 <1% 29 $410.31
87076 <1% 44 $406.79
85670 <1% 94 $403.86
82985 <1% 42 $395.15
83625 <1% 44 $372.62
82375 <1% 61 $367.66
85461 <1% 57 $366.62
80195 <1% 42 $366.06
86005 <1% 30 $334.38
86063 <1% 99 $332.05
84145 <1% 17 $314.89
86403 <1% 52 $311.62
83945 <1% 36 $306.35
87279 <1% 25 $306.00
89230 <1% 138 $291.37
87207 <1% 45 $269.14
80157 <1% 27 $254.87
84140 <1% 16 $251.23
84105 <1% 82 $243.80
82705 <1% 78 $240.67
85378 <1% 43 $239.47
84252 <1% 13 $232.33
87280 <1% 26 $223.96
87341 <1% 25 $202.05
82941 <1% 16 $191.20
85460 <1% 36 $190.32
82495 <1% 29 $189.30
86161 <1% 13 $155.37
86628 <1% 14 $154.52
83785 <1% 12 $135.42
85008 <1% 57 $123.28
86226 <1% 12 $116.78
83527 <1% 12 $111.80
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 425 $109.63
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 90 $95.70
82374 <1% 26 $83.98
85396 <1% 12 $62.32
84030 <1% 12 $32.40
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKOLOZSVARY, JOHN (EXECUTIVE DIRECTOR)